Phase II Randomized Double Blind Clinical Trial of Imatinib Mesylate STI571 (Glivec) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.

Trial Profile

Phase II Randomized Double Blind Clinical Trial of Imatinib Mesylate STI571 (Glivec) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2014

At a glance

  • Drugs Imatinib (Primary)
  • Indications Scleroderma; Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms SCLEROGLIVEC
  • Most Recent Events

    • 09 May 2014 New trial record
    • 03 Mar 2011
    • 23 Jan 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top